Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    8978299 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)

Study has passed its completion date and status has not been verified in more than two years.